Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Volitionrx (VNRX) Common Equity (2018 - 2025)

Volitionrx filings provide 11 years of Common Equity readings, the most recent being -$35.6 million for Q4 2025.

  • On a quarterly basis, Common Equity fell 36.33% to -$35.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$35.6 million, a 36.33% decrease, with the full-year FY2025 number at -$35.6 million, down 36.33% from a year prior.
  • Common Equity hit -$35.6 million in Q4 2025 for Volitionrx, down from -$34.6 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $31.2 million in Q1 2021 to a low of -$35.6 million in Q4 2025.
  • Median Common Equity over the past 5 years was -$3.1 million (2022), compared with a mean of -$5.9 million.
  • Biggest five-year swings in Common Equity: soared 239.27% in 2021 and later plummeted 694.03% in 2024.
  • Volitionrx's Common Equity stood at $17.7 million in 2021, then crashed by 117.64% to -$3.1 million in 2022, then crashed by 178.62% to -$8.7 million in 2023, then tumbled by 199.67% to -$26.1 million in 2024, then crashed by 36.33% to -$35.6 million in 2025.
  • The last three reported values for Common Equity were -$35.6 million (Q4 2025), -$34.6 million (Q3 2025), and -$33.1 million (Q2 2025) per Business Quant data.